These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 36529272)

  • 1. Real-Life Experience of Secukinumab in Patients With Hidradenitis Suppurativa.
    Melgosa Ramos FJ; García-Ruiz R; Gegúndez Hernández H; Mateu-Puchades A
    Actas Dermosifiliogr; 2023 Apr; 114(4):360-362. PubMed ID: 36529272
    [No Abstract]   [Full Text] [Related]  

  • 2. Real-Life Experience of Secukinumab in Patients With Hidradenitis Suppurativa.
    Melgosa Ramos FJ; García-Ruiz R; Gegúndez Hernández H; Mateu-Puchades A
    Actas Dermosifiliogr; 2023 Apr; 114(4):T360-T362. PubMed ID: 36764387
    [No Abstract]   [Full Text] [Related]  

  • 3. Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: Results of an open-label trial.
    Casseres RG; Prussick L; Zancanaro P; Rothstein B; Joshipura D; Saraiya A; Turkowski Y; Au SC; Alomran A; Abdat R; Abudu M; Kachuk C; Dumont N; Gottlieb AB; Rosmarin D
    J Am Acad Dermatol; 2020 Jun; 82(6):1524-1526. PubMed ID: 32044410
    [No Abstract]   [Full Text] [Related]  

  • 4. Severe hidradenitis suppurativa successfully treated with secukinumab.
    Głowaczewska A; Szepietowski JC; Matusiak Ł
    Dermatol Ther; 2020 Nov; 33(6):e13845. PubMed ID: 32544258
    [No Abstract]   [Full Text] [Related]  

  • 5. International Hidradenitis Suppurativa Severity Scoring System (IHS4) as a holistic measure of hidradenitis suppurativa disease severity compared with Hurley staging: A post hoc analysis of the SUNRISE and SUNSHINE phase 3 trials of secukinumab.
    Zouboulis CC; Prens EP; Sayed CJ; Molina-Leyva A; Bettoli V; Romanelli M; Szepietowski JC; Martinez AL; Kasparek T; Lobach I; Wozniak MB; Ortmann CE; Thomas N; Bachhuber T; Ravichandran S; Tzellos T
    J Eur Acad Dermatol Venereol; 2024 Jun; 38(6):e496-e499. PubMed ID: 38058224
    [No Abstract]   [Full Text] [Related]  

  • 6. Secukinumab treatment of hidradenitis suppurativa: questions remain.
    Endo M; Kami M
    Lancet; 2024 Feb; 403(10427):617. PubMed ID: 38368011
    [No Abstract]   [Full Text] [Related]  

  • 7. Secukinumab treatment of hidradenitis suppurativa: questions remain.
    Maul JT; Kolios AGA; Thomsen SF; Ring HC
    Lancet; 2024 Feb; 403(10427):616-617. PubMed ID: 38368009
    [No Abstract]   [Full Text] [Related]  

  • 8. Secukinumab is effective in a patient on haemodialysis for end-stage renal disease and severe hidradenitis suppurativa.
    Abu Rached N; Ocker L; Stockfleth E; Bechara FG
    J Eur Acad Dermatol Venereol; 2024 Sep; 38(9):e753-e754. PubMed ID: 38376098
    [No Abstract]   [Full Text] [Related]  

  • 9. An evaluation of secukinumab for the treatment of moderate-to-severe hidradenitis suppurativa.
    Stergianou D; Kanni T; Damoulari C; Giamarellos-Bourboulis EJ
    Expert Opin Biol Ther; 2024 Apr; 24(4):225-232. PubMed ID: 38602836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Moderate to Severe Hidradenitis Suppurativa Successfully Treated With Secukinumab.
    Villegas-Romero I; Collantes-Rodríguez C; Valenzuela-Ubiña S; Jiménez-Gallo D
    Actas Dermosifiliogr (Engl Ed); 2020 Oct; 111(8):696-698. PubMed ID: 32553985
    [No Abstract]   [Full Text] [Related]  

  • 11. Hidradenitis suppurativa outcome measures and treatment goals.
    Ingram JR
    Br J Dermatol; 2014 Dec; 171(6):1293-4. PubMed ID: 25523257
    [No Abstract]   [Full Text] [Related]  

  • 12. Secukinumab may be remedy for systemic amyloidosis findings secondary to hidradenitis suppurativa.
    Tas-Aygar G; Gonul M; Ozcan I; Ayli MD; Ertoy-Baydar D
    Dermatol Ther; 2020 Nov; 33(6):e14205. PubMed ID: 32829493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tildrakizumab in the treatment of moderate-to-severe hidradenitis suppurativa.
    Kok Y; Nicolopoulos J; Howard A; Varigos G; Kern J; Dolianitis C
    Australas J Dermatol; 2020 Nov; 61(4):e488-e490. PubMed ID: 32627843
    [No Abstract]   [Full Text] [Related]  

  • 14. Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa.
    Prussick L; Rothstein B; Joshipura D; Saraiya A; Turkowski Y; Abdat R; Alomran A; Zancanaro P; Kachuk C; Dumont N; Gottlieb AB; Rosmarin D
    Br J Dermatol; 2019 Sep; 181(3):609-611. PubMed ID: 30801662
    [No Abstract]   [Full Text] [Related]  

  • 15. Immune Classification of Hidradenitis Suppurativa: Modulation by Secukinumab.
    Stergianou D; Micha S; Tzanetakou V; Kanni T; Gkavogianni T; Katoulis A; Giamarellos-Bourboulis EJ
    J Invest Dermatol; 2023 Dec; 143(12):2518-2520.e3. PubMed ID: 37211202
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term secukinumab efficacy in patients with moderate to severe hidradenitis suppurativa: A retrospective single-centre case series (23 patients).
    Melgosa Ramos FJ; García Ruiz R; Estébanez Corrales A; Mateu Puchades A
    J Eur Acad Dermatol Venereol; 2023 Apr; 37(4):e517-e519. PubMed ID: 36268711
    [No Abstract]   [Full Text] [Related]  

  • 17. Delayed drug hypersensitivity reaction to secukinumab in a patient with hidradenitis suppurativa.
    Konda S; Shetty N; Friedman B; Veenstra J
    Drug Ther Bull; 2024 Apr; 62(5):77-79. PubMed ID: 37407276
    [No Abstract]   [Full Text] [Related]  

  • 18. Secukinumab treatment of hidradenitis suppurativa: questions remain - Authors' reply.
    Kimball AB; Ravichandran S;
    Lancet; 2024 Feb; 403(10427):617-618. PubMed ID: 38368012
    [No Abstract]   [Full Text] [Related]  

  • 19. Moderate to severe hidradenitis suppurativa treated with biological therapies.
    Chinniah N; Cains GD
    Australas J Dermatol; 2014 May; 55(2):128-31. PubMed ID: 24456051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psoriasis Onset during Anti-TNF Treatment for Hidradenitis Suppurativa: Successful Remission of Both Conditions with Secukinumab.
    Kontochristopoulos G; Kanni T; Marnelakis I; Agiasofitou E; Liakou A; Rigopoulos D
    Skinmed; 2023; 21(1):57-58. PubMed ID: 36987833
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.